Kitichotkul Kit, Lertprasertsuke Nirush, Kintarak Sompid, Pongsiriwet Surawut, Powcharoen Warit, Iamaroon Anak
Department of Oral and Maxillofacial, Faculty of Dentistry, Chiang Mai University, Chiang Mai, Thailand.
Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Heliyon. 2022 Sep 17;8(10):e10667. doi: 10.1016/j.heliyon.2022.e10667. eCollection 2022 Oct.
This study aimed to investigate the expression of programmed death-ligand 1 (PD-L1) and its associations with human papillomavirus (HPV) 16/18 DNA status, p16 expression, demographic, clinicopathologic and risk parameters in patients with oral squamous cell carcinoma (OSCC).
A total of 85 formalin-fixed, paraffin-embedded OSCC specimens were collected. HPV16/18 DNA was detected by polymerase chain reaction. PD-L1 and p16 expressions were assessed using immunohistochemical technique. The immunostaining scores were calculated by combined positive score (CPS), previously described. The positive scoring value was determined at CPS ≥1, recommended by FDA. The associations between PD-L1 expression and HPV16/18 DNA status, p16 expression, demographic, clinicopathologic, and risk parameters were analyzed by Chi-square, Fisher's exact tests, and multivariate logistic regression.
PD-L1 expression was detected in 22 out of 85 cases of OSCC (25.9%). 16.5% of all cases were HPV 16/18-positive and 62.4% were p16-positive. Statistically, there were no significant associations between PD-L1 expression in OSCC and HPV16/18 DNA status, p16 expression, demographic and, clinicopathologic parameters or risk behaviors.
Approximately one-fourth of OSCC cases were PD-L1-positive, suggesting candidacy for anti-PD-L1 immunotherapy. Furthermore, HPV infection and p16 expression were not involved with PD-L1 expression. Further clinical trials warrant the benefits of immunotherapy in patients with PD-L1-positive OSCC.
本研究旨在调查程序性死亡配体1（PD-L1）的表达及其与口腔鳞状细胞癌（OSCC）患者人乳头瘤病毒（HPV）16/18 DNA状态、p16表达、人口统计学、临床病理和风险参数之间的关系。
共收集85例福尔马林固定、石蜡包埋的OSCC标本。采用聚合酶链反应检测HPV16/18 DNA。使用免疫组织化学技术评估PD-L1和p16的表达。免疫染色评分通过先前描述的联合阳性评分（CPS）计算。阳性评分值根据美国食品药品监督管理局（FDA）的建议确定为CPS≥1。通过卡方检验、Fisher精确检验和多因素逻辑回归分析PD-L1表达与HPV16/18 DNA状态、p16表达、人口统计学、临床病理和风险参数之间的关系。
85例OSCC病例中有22例（25.9%）检测到PD-L1表达。所有病例中16.5%为HPV 16/18阳性，62.4%为p16阳性。统计学上，OSCC中PD-L1表达与HPV16/18 DNA状态、p16表达、人口统计学、临床病理参数或风险行为之间无显著关联。
约四分之一的OSCC病例为PD-L1阳性，提示其可能适合接受抗PD-L1免疫治疗。此外，HPV感染和p16表达与PD-L1表达无关。进一步的临床试验有必要验证免疫治疗对PD-L1阳性OSCC患者的益处。
